Key result
Bosentan completely prevents experimental overcirculation-induced pulmonary arterial hypertension.
Why the study?
Experimental overcirculation-induced pulmonary arterial hypertension is causally related to activation of the pulmonary ET-1 system and may be preventable by endothelin receptor antagonism.
Does bosentan prevent overcirculation-induced experimental pulmonary arterial hypertension?
Does bosentan prevent overcirculation-induced experimental pulmonary arterial hypertension?
Bosentan completely prevents overcirculation-induced pulmonary arterial hypertension in an experimental model, suggesting a causal role for the pulmonary ET-1 system.
Bosentan for PAH prevention remains unproven in humans; leaves open translation of experimental ET-1 blockade to clinical overcirculation models.
Experimental overcirculation-induced pulmonary arterial hypertension appears to be causally related to an activation of the pulmonary ET-1 system and as such is completely prevented by the dual endothelin receptor antagonist bosentan.
No takes yet. Share an insight, caveat, or question.
Rondelet et al. (2003) studied this question. Bosentan, a dual endothelin receptor antagonist, completely prevented experimental overcirculation-induced pulmonary arterial hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: